根据HepQuant-SHUNT的评估,肝胆酸盐清除与Fontan循环患者的临床结果有关
Yuli Y Kim1,2, Daniel Ganger3, Alexis Z Tomlinson4
1Division of Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
International journal of cardiology. Congenital heart disease
|February 16, 2026
概括
在Fontan循环 (FC) 患者中,SHUNT%的升高表明门腔血液的分流增加,导致无移植生存率显著降低,并增加不良临床事件的风险. 这项措施有效地识别高风险个人,以获得中期结果.
科学领域:
- 心脏病学 心脏病学
- 肝病学 肝病学是一种肝病学.
- 医疗成像医学成像
背景情况:
- 丰坦相关性肝病 (FALD) 是丰坦循环 (FC) 患者的普遍并发症.
- 双胆酸盐清除试验提供了一种非侵入性,流量依赖的肝功能评估.
研究的目的:
- 调查胆酸盐清除率,特别是SHUNT%,与患有FC的成年人的临床结果之间的关联.
- 为了确定SHUNT%是否可以预测本种群的不良事件和生存率.
主要方法:
- 一项前性研究招募了50名患有FC的成年人 (≥18岁).
- 肝脏胆酸盐清除率被测量以计算SHUNT%,SHUNT%的升高定义为>30%.
- 使用生存分析和回归模型,分析了与SHUNT%相关的无移植生存率和不良事件的复合.
主要成果:
- 招募了50名参与者,5年无移植生存率为79%.
- 较高的SHUNT%与较低的5年无移植生存率显著相关.
- 患有SHUNT%升高的患者患有复合不良结果的几率增加了3.9倍 (死亡,移植,心力衰竭,,失去蛋白质的肠道病变或肝细胞癌).
结论:
- 增加的门血分流,用SHUNT%量化,与CF患者的无移植生存率降低有关.
- SHUNT%在识别有中期不良临床事件风险的患者方面表现出极好的歧视能力.
- 这种非侵入性肝功能测试可以帮助Fontan患者的风险分层.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
257
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
257
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
212
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
212
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance
570
Hepatic clearance refers to the volume of blood cleared of a drug by the liver per unit of time. It plays a crucial role in drug metabolism and elimination. While hepatic clearance is commonly estimated by subtracting renal clearance from total body clearance, other pathways, such as pulmonary or biliary clearance, may also contribute. However, these pathways are generally less significant than hepatic and renal clearance.
Most drugs undergo restrictive clearance, which is proportional to the...
Most drugs undergo restrictive clearance, which is proportional to the...
570
Hepatic Drug Clearance: Role of Transporters
328
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
328
Hepatic Drug Clearance: Effect of Protein Binding
586
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
586
One-Compartment Open Model for IV Bolus Administration: Estimation of Clearance
383
Clearance is a key pharmacokinetic parameter that quantifies the volume of body fluid from which a drug is entirely removed within a specific time frame. It is crucial in assessing how a drug is eliminated from the body and has critical clinical applications.
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
383


